Updates are available Correction dated 2022-03-11
Click to view Correction: https://doi.org/10.1038/s41590-022-01178-2
-
Authors
McCaffrey, Erin F. http://orcid.org/0000-0001-7241-1798
Donato, Michele http://orcid.org/0000-0002-9968-6027
Keren, Leeat
Chen, Zhenghao
Delmastro, Alea http://orcid.org/0000-0002-7959-3165
Fitzpatrick, Megan B. http://orcid.org/0000-0001-7040-8018
Gupta, Sanjana
Greenwald, Noah F. http://orcid.org/0000-0002-7836-4379
Baranski, Alex
Graf, William http://orcid.org/0000-0002-4264-9479
Kumar, Rashmi
Bosse, Marc
Fullaway, Christine Camacho http://orcid.org/0000-0002-4924-591X
Ramdial, Pratista K.
Forgó, Erna
Jojic, Vladimir
Van Valen, David http://orcid.org/0000-0001-7534-7621
Mehra, Smriti
Khader, Shabaana A. http://orcid.org/0000-0002-9545-4982
Bendall, Sean C. http://orcid.org/0000-0003-1341-2453
van de Rijn, Matt
Kalman, Daniel
Kaushal, Deepak http://orcid.org/0000-0003-3521-1257
Hunter, Robert L.
Banaei, Niaz
Steyn, Adrie J. C.
Khatri, Purvesh http://orcid.org/0000-0002-4143-4708
Angelo, Michael http://orcid.org/0000-0003-1531-5067
-
Funding
Funding for this research was provided by:
U.S. Department of Defense (W81XWH2110143, W81XWH-18-1-0253, W81XWH1910235)
Wellcome Trust
Bill and Melinda Gates Foundation (OPP1113682)
U.S. Department of Health & Human Services | National Institutes of Health (5DP5OD01982205, 1R01CA24063801A1, 5R01AG06827902, 5UH3CA24663303, 5R01CA22952904, 1U24CA22430901, 5R01AG05791504, 5R01AG05628705, 5T32AI007290)
Cancer Research Institute
Parker Center for Cancer Immunotherapy, Breast Cancer Research Foundation
National Science Foundation (2017242837)
Damon Runyon Cancer Research Foundation (DRG-2292-17)
European Molecular Biology Organization (ALTF 1128–2016)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA246880-01)
CRDF Global
South African Medical Research Council
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (1U19AI109662, U19AI057229, 5R01AI125197)
Dr. Ralph and Marian Falk Medical Research Trust
- License Information
-
More Information
Article History
Received: 25 May 2021
Accepted: 14 December 2021
First Online: 20 January 2022
Change Date: 11 March 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41590-022-01178-2
Competing interests
: M.A. and S.C.B. are inventors on patent US20150287578A1, which covers the mass spectrometry approach utilized by MIBI-TOF to detect elemental reporters in tissue using secondary ion mass spectrometry. M.A. and S.C.B. are board members and shareholders in IonPath, which develops and manufactures the commercial MIBI-TOF platform. E.F.M. has previously consulted for IonPath. The remaining authors declare no competing interests.
